Clinical stage anti-RGMa monoclonal antibody elezanumab promotes bladder recovery and neuroplasticity after traumatic spinal cord injury
{{output}}
Spinal cord injury (SCI) causes severe and often permanent neurological deficits, including neurogenic lower urinary tract dysfunction. Although restoration of bladder function is a major clinical priority after SCI and would profoundly improve care and qualit... ...
